Home › Research › Biomarkers
Amyloid imaging: the court of public opinion
Lerner AJ.. Neurology, 2013-08-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Human amyloid imaging is one of the great recent translational medicine stories. Beginning with the recognition that Thioflavin T derivatives could be used as PET tracers, through development of Pittsburgh compound B, to Food and Drug Administration (FDA) approval of Florbetapir in 2012, human amyloid imaging has held great promise to allow in vivo inclusive diagnosis of Alzheimer disease (AD), even though the first principle of amyloid PET is that it functions as a surrogate for β-amyloid pathology, and not necessarily as a surrogate for the diagnosis of AD.(1,2.)
What this study adds
Evidence grade: Low
Amyloid PET imaging lets doctors see beta-amyloid in the living brain, but the authors note it is a surrogate for amyloid pathology and not necessarily a surrogate for an Alzheimer's diagnosis. This paper is a commentary on the history and public perception of amyloid imaging, not a study of a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lerner, A. J. (2013). Amyloid imaging: the court of public opinion. Neurology. https://doi.org/10.1212/wnl.0b013e3182a55fe3
Vancouver
Lerner AJ. Amyloid imaging: the court of public opinion. Neurology. 2013. doi:10.1212/wnl.0b013e3182a55fe3. PMID: 23966257.
BibTeX
@article{lerner2013-23966257,
author = {Lerner, A. J.},
title = {{Amyloid imaging: the court of public opinion}},
journal = {Neurology},
year = {2013},
doi = {10.1212/wnl.0b013e3182a55fe3},
pmid = {23966257},
url = {https://doi.org/10.1212/wnl.0b013e3182a55fe3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Human amyloid imaging is one of the great recent translational medicine stories.
- Beginning with the recognition that Thioflavin T derivatives could be used as PET tracers, through development of Pittsburgh compound B, to Food and Drug Administration (FDA) approval of Florbetapir in 2012, human amyloid imaging has held great promise to allow in vivo inclusive diagnosis of Alzheimer disease (AD), even though the first principle of amyloid PET is that it functions as a surrogate for β-amyloid pathology, and not necessarily as a surrogate for the diagnosis of AD.(1,2.)
Why it matters
Amyloid PET imaging lets doctors see beta-amyloid in the living brain, but the authors note it is a surrogate for amyloid pathology and not necessarily a surrogate for an Alzheimer's diagnosis. This paper is a commentary on the history and public perception of amyloid imaging, not a study of a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 34 of the 94 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Alan Jay Lerner: h-index 70 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Case Western Reserve University: institution h-index 1,159 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23966257) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 94 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.